Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
Tsubasa Takizawa(Keio University), Jin Nakahara(Keio University Hospital), Chisato Iba(Keio University Hospital), Naoki Miyazaki(Keio University Hospital), Mamoru Shibata(Tokyo Dental College Ichikawa General Hospital), Narumi Watanabe(Keio University Hospital), Satoko Hori(Keio University), Ryo Takemura(Keio University Hospital), Seiya Ohtani(Keio University), Koji Sekiguchi(Keio University Hospital), Kei Ishizuchi(Keio University Hospital)
Cited by 67
Related Papers
Hallmarks of primary headache: part 1 – migraine
|The Journal of Headache and Pain|2024|174
Spreading depolarizations trigger caveolin‐1–dependent endothelial transcytosis
|Annals of Neurology|2018|107
International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
|Cephalalgia|2024|107
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
|Cephalalgia|2024|106
Spreading depression as a preclinical model of migraine
|The Journal of Headache and Pain|2019|104